The endogenous cannabinoid (endocannabinoid) system 1 consists of two G protein-coupled receptors, CB 1 and CB 2 , and their natural lipid ligands, N-arachidonoylethanolamine (anandamide) 2 and 2-arachidonoyglycerol (2-AG) 3, 4 . The CB 1 receptor is highly expressed throughout the nervous system, where it mediates most of the neurobehavioral effects of cannabinoid agonists, such as Δ9-tetrahydrocannabinol (THC), the primary psychoactive component of marijuana 5 . The CB 2 receptor is only sparsely expressed in the brain and is instead found mainly on immune cells 5 . Unlike most other neurotransmitters, which are water soluble and stored in membrane-delineated vesicles before release, the endocannabinoids anandamide and 2-AG are hydrophobic neutral lipids that appear to be biosynthesized and released at the moment of their intended action (on-demand production 6 ). These features indicate that the enzymes involved in endocannabinoid production and degradation are important regulators of signaling 7-9 . For instance, genetic 10,11 or pharmacological 12-15 disruption of fatty acid amide hydrolase (FAAH), the principal degradative enzyme for anandamide 16 , elevates brain levels of anandamide and produces CB 1 -dependent analgesia in multiple pain assays. A similar outcome is observed following acute blockade of the 2-AG-degrading enzyme MAGL, which raises 2-AG levels in the nervous system and reduces pain behavior 17, 18 . Inhibition of MAGL, however, causes additional behavioral effects that are not observed following FAAH blockade, including hypomotility and hyperreflexia 17, 19 , which suggest that the enzyme has a broader effect on the brain cannabinoid system. In further support of this premise, MAGL inhibitors, but not FAAH inhibitors, augment depolarization-induced suppression of inhibition (DSI) 20 and excitation (DSE) 20, 21 , forms of synaptic plasticity that have been shown to require the CB 1 receptor 22 and the 2-AG biosynthetic enzyme diacylglycerol lipase-α 23,24 .
1 1 1 4 VOLUME 13 | NUMBER 9 | SEPTEMBER 2010 nature neurOSCIenCe a r t I C l e S these two major endocannabinoid pathways in the nervous system that result in either sustained agonism or functional antagonism. That these effects occur through the same receptor (CB 1 ) suggests that ligand diversification is an important mechanism by which the endocannabinoid system modulates mammalian physiology and behavior.
RESULTS

Mouse models for chronic inactivation of MAGL
We established complementary pharmacological and genetic models to examine the consequences of sustained elevations in 2-AG in the nervous system. We generated a chronic pharmacological model by treating mice for six consecutive days with the MAGL inhibitor JZL184 (40 mg per kg of body weight, intraperitoneal, one dose per day), which has previously been shown to selectively inactivate MAGL in the nervous system and increase the level of 2-AG in the brain by up to tenfold that of control levels 17 . Mice treated with JZL184 acutely (single dose) or chronically showed highly elevated levels of 2-AG in the brain 2 h following final dosing (Fig. 1a) . This increase in brain 2-AG levels persisted for at least 26 h (Supplementary Fig. 1 ), indicating that 2-AG remained elevated throughout the repeated dosing regime. Chronic, but not acute, dosing also caused a modest elevation in anandamide (~threefold) 2 h after final treatment (Fig. 1a) , likely reflecting a partial blockade of FAAH 17 as a result of cumulative exposure to JZL184 over the treatment regimen. This change was, however, much lower than the 15-fold rise in brain anandamide that we observed in mice treated for 1 or 6 d with the selective FAAH inhibitor PF-3845 (10 mg per kg, intraperitoneal, one dose per day; Fig. 1a ) 15 and was not of prolonged duration (Supplementary Fig. 1 ). PF-3845 did not alter brain 2-AG levels after acute or chronic treatment (Fig. 1a) .
We also employed Mgll −/− mice as a complementary genetic model for sustained elevations in 2-AG. We obtained Mgll −/− mice generated by gene trapping from the Texas A&M Institute for Genomic Medicine (Fig. 1b,c) and confirmed by activity-based protein profiling 26, 27 that these mice lack detectable MAGL activity without showing alterations in other brain serine hydrolase activities, including FAAH ( Fig. 1d and Supplementary Fig. 2 ). We also confirmed the absence of MAGL expression in Mgll −/− mice by in situ hybridization and mass spectrometry-based proteomics (Supplementary Fig. 3 ). Mgll −/− mice exhibited marked (~90%) reductions in brain 2-AG hydrolytic activity ( Fig. 1e and Supplementary Fig. 2 ) and about tenfold elevations in brain 2-AG levels ( Fig. 1f and Supplementary Table 1 ). Brain arachidonic acid levels were also reduced in Mgll −/− mice ( Fig. 1f and Supplementary Table 1 ) or mice treated acutely or chronically with JZL184 ( Supplementary Fig. 2 ), consistent with previous findings designating 2-AG as a physiological precursor for arachidonic acid in the brain 17, 28 . Anandamide levels were unaltered in Mgll −/− mice ( Fig. 1f and Supplementary Table 1) . We observed similar metabolic changes in a panel of peripheral tissues from JZL184-treated 29 or Mgll −/− mice, all of which showed reductions in 2-AG hydrolysis and elevations in 2-AG, but not anandamide ( Supplementary Fig. 4 ). These data provide genetic confirmation that MAGL is the principal 2-AG hydrolase in the mouse brain and many peripheral tissues and establish Mgll −/− mice as a valid animal model for examining the neurophysiological and behavioral consequences of sustained elevations in 2-AG.
Chronic MAGL blockade causes tolerance in pain assays
Acute pharmacological blockade of MAGL or FAAH produced similar efficacy in multiple pain assays (Fig. 2) , including antinociception in the acute thermal tail-withdrawal test (Fig. 2a) and reductions in mechanical (Fig. 2b) and cold ( Fig. 2c ) allodynia in the chronic constrictive injury of the sciatic nerve (CCI) model. In contrast, prolonged disruption of these enzymes resulted in a marked difference in the expression of tolerance. Although mice treated repeatedly with PF-3845 maintained hypoalgesic (Fig. 2a) and anti-allodynic . Data are presented as means ± s.e.m. *P < 0.05, **P < 0.01 and ***P < 0.001 versus vehicle-treated (a) or wild-type littermate control mice (e,f) (Dunnett's post hoc test). a r t I C l e S (Fig. 2b,c) responses, mice chronically treated with JZL184 showed similar pain responses as control mice (Fig. 2a-c) . Similarly, Mgll −/− mice displayed equivalent tail-withdrawal latencies as Mgll +/+ and Mgll +/− mice (Fig. 2d) .
These findings indicate that the analgesic effects produced by acute blockade of MAGL are lost following sustained inactivation of this enzyme. We next investigated whether this form of tolerance was a result of alterations in the endocannabinoid system.
Chronic MAGL blockade causes tolerance to CB 1 agonists
We assessed the behavioral effects of cannabinoid receptor agonists in mice with chronic disruptions in FAAH or MAGL. Faah −/− mice 10 , as well as mice that were chronically treated with PF-3845 ( Supplementary Fig. 5 ), exhibited wild-type responses to cannabinoids in antinociception, hypothermia and catalepsy assays, indicating that CB 1 function was normal. In contrast, Mgll −/− mice or mice treated chronically with JZL184 showed reduced responses to the antinociceptive and hypothermic effects of THC ( Supplementary  Fig. 6 ) and the full CB 1 agonist WIN55,212-2 (Fig. 3) . Chronic JZL184 treatment also elicited marked cross-tolerance to the anti-allodynic effects of WIN55,212-2 and PF-3845 in the CCI model (Fig. 2e,f) . CB 1 agonist-induced catalepsy was less affected by sustained inactivation of MAGL (Fig. 3c,f and Supplementary Fig. 6 ). These data indicate that sustained inactivation of MAGL causes cross-tolerance to exogenous CB 1 agonists and to a FAAH inhibitor in a neuropathic pain model.
We next asked whether prolonged MAGL or FAAH blockade produces physical dependence, a phenotype that has been observed in rodents that have been exposed to repeated treatments with direct CB 1 agonists 30 . The CB 1 receptor antagonist rimonabant precipitated paw flutters in mice that were chronically treated with JZL184 to a similar degree as mice subjected to a mild THC chronic dosing regimen (10 mg per kg per day for 6 d; Supplementary Fig. 7 ). In contrast, rimonabant did not precipitate paw tremors in mice that were chronically administered PF-3845.
Brain CB 1 receptors are impaired by chronic MAGL blockade The loss of analgesic responses and occurrence of cannabinoid crosstolerance in mice with sustained disruptions of MAGL suggested that CB 1 receptors might be downregulated and/or desensitized in these mice. In support of this hypothesis, brain tissue from Mgll −/− mice or mice chronically treated with JZL184 showed decreases in CB 1 receptor number and function, as measured by specific binding of To provide further evidence that the behavioral tolerance and CB 1 receptor adaptations caused by chronic MAGL blockade were the results of elevated 2-AG acting on CB 1 receptors (as opposed to other metabolic alterations, such as reductions in arachidonic acid), we attempted to block these changes by concurrent chronic treatment with rimonabant. For technical reasons, we focused on antinociception for our behavioral measurements (Supplementary Discussion). Over a 6-d period, we treated mice daily with vehicle, JZL184 (40 mg per kg, intraperitoneal), rimonabant (3 mg per kg, intraperitoneal), or both JZL184 (40 mg per kg, intraperitoneal) and rimonabant (3 mg per kg, intraperitoneal), yielding four treatment groups. As shown previously ( Fig. 3) , chronic JZL184-treated mice produced marked tolerance to the anti-nociceptive effects of WIN55,212-2 ( Supplementary Fig. 9 ). In contrast, the rimonabant-JZL184-treated mice exhibited greater antinociceptive responses to WIN55,212-2 that were close in magnitude to those observed in control (vehicle or rimonabant) mice (Supplementary Fig. 9 ). These data indicate that daily treatment with rimonabant substantially prevents the nociceptive adaptations caused by chronic MAGL blockade. Rimonabant treatment (10 mg per kg, intraperitoneal) also ameliorated brain CB 1 receptor adaptations in chronic JZL184-treated mice, as determined by CP55,940-stimulated [ 35 S]-GTPγS binding ( Supplementary Fig. 9) .
A more extensive regional analysis of CP55,940-stimulated [ 35 S]GTPγS binding in mice treated chronically with either vehicle or JZL184 revealed that sustained MAGL blockade produced a heterogeneous reduction in CB 1 function throughout the brain (Fig. 5) . Notable brain regions showing CB 1 desensitization included the cingulate cortex, hippocampus, somatosensory cortex and PAG (Fig. 5b) . In contrast, chronic JZL184 treatment did not elicit desensitization in the caudate putamen or globus pallidus. These data, taken together, indicate that prolonged inactivation of MAGL, but not FAAH, causes marked changes in CB 1 receptor expression and function in specific brain regions, including those that participate in pain perception (for example, the PAG) and cognitive/emotional processing of pain 33 (for example, cingulate cortex). a r t I C l e S Synaptic plasticity is impaired by chronic MAGL blockade Endocannabinoids regulate several forms of synaptic plasticity 34 , including DSI in the hippocampus 20 . Considering that CB 1 receptors were impaired in this brain region by sustained MAGL inactivation, we asked whether DSI was also affected. In contrast with previous findings that acute inhibition of MAGL by bath application of JZL184 potentiates DSI in mouse hippocampal slices 20 , we observed decreases in the magnitude and time constant (τ) of DSI in hippocampal slices from mice chronically treated with JZL184 when compared with slices from vehicletreated mice (Fig. 6a) . We observed similar effects in layer V pyramidal neurons of the cingulate cortex, where acute (Supplementary Fig. 10 ) and chronic (Fig. 6b) treatment with JZL184 potentiated and disrupted DSI, respectively. PF-3845 did not affect DSI in the hippocampus (Fig. 6a) or cingulate cortex ( Fig. 6b and Supplementary Fig. 10 ). The attenuation of DSI by chronic JZL184 treatment is consistent with desensitization of CB 1 receptors in the affected neuronal circuits (Fig. 5) . In support of this premise, CP55,940 (3 μM) induced less depression of inhibitory postsynaptic currents (IPSCs) in the hippocampal CA1 pyramidal neurons or layer V pyramidal neurons of the cingulate cortex from chronically JZL184-treated mice than in those from vehicle-treated mice (Fig. 6c,d) . In contrast, repeated in vivo administration of PF-3845 did not alter CP55,940-induced depression of IPSCs in either hippocampus (Fig. 6c) or cingulate cortex (Fig. 6d) . The CB 1 receptor antagonist AM251 (2 μM) completely blocked CP55,940-induced depression of IPSCs in both brain regions (Supplementary Fig. 11) . Notably, chronic JZL184 treatment exerted only a modest effect that did not reach statistical significance (P > 0.05) on CP55,940-induced depression of IPSCs in the caudate putamen (Supplementary Fig. 12 ), a brain region that also showed minimal CB 1 receptor adaptations (Fig. 5) .
Recent studies have suggested that CB 1 receptors on glutamatergic synapses mediate many of the behavioral effects of CB 1 agonists 35 . We therefore examined whether chronic JZL184 or PF-3845 treatment altered CB 1 -mediated depression of glutamatergic excitatory transmission in the hippocampus. Chronic JZL184, but not PF-3845, treatment attenuated CP55,940-induced depression of field excitatory postsynaptic potentials (fEPSPs) in the CA1 region of the hippocampus (Supplementary Fig. 13 ).
These results, taken together, indicate that sustained inactivation of MAGL, but not FAAH, impairs specific endocannabinoid-mediated forms of synaptic plasticity. That we observed these effects for both glutamatergic and GABAergic transmission is consistent with previous findings that acute MAGL, but not FAAH, blockade enhances both DSE and DSI 20 and that diacylglycerol lipase-α knockout mice exhibit defects in both DSE and DSI 23, 24 .
DISCUSSION
Prolonged treatment with THC and other cannabinoid receptor agonists leads to the development of tolerance and physical dependence 36 and these behavioral phenotypes have been shown to be mirrored by substantial reductions in CB 1 receptor expression and activity in the brain 37, 38 . We found that sustained elevations in brain 2-AG caused by either genetic deletion or chronic pharmacological blockade of MAGL also produced substantial functional antagonism of the brain endocannabinoid system, as manifested by tolerance to the analgesic effects of acute enzyme inhibition, cross-tolerance to CB 1 receptor agonists, a reduction in CB 1 receptor expression and function, and disruptions in endocannabinoid-dependent synaptic plasticity. This profile markedly contrasted with that of sustained pharmacological disruption of FAAH, which caused persistent analgesic effects without evidence of tolerance or changes in CB 1 receptor expression or function. Thus, brain CB 1 receptors undergo markedly different adaptations in response to sustained elevations of the two principal endocannabinoids, 2-AG and anandamide.
That the cannabinoid cross-tolerance and alterations in CB 1 receptor function caused by JZL184 were both attenuated by co-treatment with rimonabant supports a model in which chronic MAGL blockade produces a sustained elevation in 2-AG that tonically activates and eventually desensitizes CB 1 receptors in the brain. We cannot, however, rule out the possibility that other metabolic changes caused by MAGL inhibition, such as reductions in arachidonic acid, also contribute to alterations in brain endocannabinoid pathways. We also note that chronic JZL184 treatment produced an evidently larger degree of cross-tolerance to CB 1 agonists (Fig. 3a,b) than genetic disruption of Mgll (Fig. 3d,e) . Although we do not yet understand the basis for this difference, it could reflect differences in background strain (C57BL/6J versus 129SvEv/C57BL/6J for the JZL184-treated and Mgll −/− mice, respectively) or the existence of compensatory mechanisms in the Mgll −/− mice that counteract the observed CB 1 receptor adaptations.
Although there are other examples of functional antagonism of receptor systems following deletion of a metabolic enzyme, including reduced activity of nicotinic receptors 39 in Ache −/− (acetylcholinesterase) mice and impairments in 5-HT1A receptors in Maoa −/− (monoamine oxidase A) mice 40 , we report the first instance, to the best of our 41 . This differential desensitization may be related to the higher efficacy of 2-AG as a full CB 1 receptor agonist (in contrast with anandamide, which acts as a partial CB 1 receptor agonist) 42 , although previous research suggests that the magnitude of CB 1 receptor desensitization is not related to the intrinsic activity of exogenous agonists 43 . Bulk brain levels of 2-AG are also much higher than anandamide (see Fig. 1a ; although the interstitial levels of these endocannabinoid are similar 44 ), and elevated 2-AG may therefore achieve greater occupancy of CB 1 receptors in vivo. Finally, MAGL and FAAH are found in different neuronal populations and subcellular compartments (pre-and postsynaptic, respectively) throughout the brain and these anatomical distinctions might also differentially affect endocannabinoid signaling pathways in the nervous system. Regardless, our observation that chronic MAGL blockade produced cross-tolerance to a FAAH inhibitor in the CCI model (Fig. 2e,f) indicates that 2-AG and anandamide pathways can crosstalk in the neural circuits that regulate pain behavior. The endocannabinoid system regulates several forms of synaptic plasticity, including DSI and DSE 34 . Acute MAGL, but not FAAH, inhibition potentiates DSI in neurons of the hippocampus 20 and cingulate cortex (Supplementary Fig. 4) . Notably, however, we found that repeated administration of JZL184 led to profound DSI deficits in these neuronal populations (Fig. 6) . These impairments in short-term synaptic plasticity are consistent with the observed alterations in CB 1 receptor function in the hippocampus and cingulate cortex (Fig. 5) , as deletion or antagonism of this receptor has been shown to abolish DSI 22, 45 . That acute and chronic inhibition of MAGL produced opposing effects on DSI in multiple brain regions supports a model in which prolonged elevations of endogenous 2-AG cause functional antagonism of CB 1 receptors in the nervous system.
In contrast with direct CB 1 agonists, which produce cross-tolerance to the antinociceptive, hypothermic and cataleptic effects of THC and WIN55,212-2 (ref. 46) , chronic MAGL disruption only caused strong cross-tolerance to the antinociceptive and hypothermic effects of these drugs. The minimal cross-tolerance to cannabinoid-induced catalepsy is consistent with the lack of CB 1 receptor desensitization in caudate putamen and globus pallidus (Fig. 5) , which are associated with cannabinoid-induced catalepsy 47 . Conversely, the tolerance that we observed to the antinociceptive effects of JZL184 and the occurrence of cross-tolerance to WIN55,212-2-and THC-induced antinociception could be attributed to the desensitization of CB 1 receptors in PAG (Fig. 5) , a brain area that has been strongly implicated in cannabinoid-induced antinociception 48 . We also note that neither MAGL nor FAAH inhibitors alone cause catalepsy; however, combined treatment with these inhibitors does promote cataleptic behavioral responses 19 . It will be interesting to determine whether sustained inactivation of both MAGL and FAAH causes cross-tolerance to the cataleptic effects of other CB 1 agonists and concomitant alterations in CB 1 receptor expression and activity in brain regions such as the caudate putamen and globus pallidus.
In summary, our data support a model in which ligand diversification is important for shaping the distinct functions and properties of endocannabinoid signaling pathways in the nervous system. The widespread behavioral and CB 1 receptor adaptations caused by chronic disruption of MAGL suggest a broad role for 2-AG throughout the nervous system. In contrast, the preservation of analgesic phenotypes and CB 1 receptor function in mice with sustained inactivation of FAAH may reflect a more limited, stress-dependent function for anandamide. This idea is also consistent with the behavioral phenotypes observed in FAAH-disrupted animals, which preferentially show reductions in pain 11 and anxiety 25 procedures with strong stress components. These discoveries may have important translational implications. Consider, for instance, that acute inhibition of FAAH and MAGL produces similar efficacy in multiple pain assays, but these effects are only sustained in chronically disrupted FAAH systems. Might this imply that MAGL is a less suitable target for treatment of pain disorders? Perhaps, but it also may be possible to achieve prolonged analgesic responses through partial MAGL blockade. In this event, one would still need to be concerned about the potential tolerance and withdrawal effects of MAGL inhibitors. That CB 1 receptors, on the other hand, are surprisingly nonadaptive to continuous elevations of brain anandamide suggests that FAAH inhibitors are capable of producing sustained analgesic activity without high risk for dependence.
METhODS
Methods and any associated references are available in the online version of the paper at http://www.nature.com/natureneuroscience/.
Note: Supplementary information is available on the Nature Neuroscience website. Activity-based protein profiling analysis. Analysis of brain proteomes pretreated with 5 μM JZL184 or DMSO vehicle (30 min at 25 °C) was performed as described previously 27 .
ONLINE METhODS
2-Ag hydrolysis assays. 2-AG hydrolytic activity of Mgll +/+ , Mgll +/− and Mgll −/− brain homogenates (n = 4 per genotype) pretreated with either 1 μM JZL184 or DMSO vehicle (30 min at 25 °C) was determined using a previously described liquid chromatography-mass spectrometry assay 27 on an Agilent 6520 QTOF MS.
Brain metabolite measurements. Brain lipid levels were determined as previously described 29 except that free fatty acid levels in Mgll +/+ , Mgll +/− and Mgll −/− brains were measured on an Agilent 1100 series LC-MS and quantified compared to a palmitic acid calibration curve.
In situ hybridization. Perfused brains from 12-week-old male Mgll +/+ and Mgll −/− mice were postfixed, cryoprotected and frozen as previously described 49 . In situ hybridization was performed on 25-μm-thick free-floating coronal sections as described 49 with [ 35 S]UTP-labeled, single-stranded antisense and sense control cRNA probes to Mgll cDNA (bases 285-600).
multidimensional lc-mS proteomic analysis. Mouse brain proteomes (0.75 mg total protein) from Mgll +/+ and Mgll −/− mice (n = 3 mice per genotype) were precipitated with 1:4 chloroform:methanol and denatured with 25 mM ammonium bicarbonate in 6 M urea. Samples were reduced with 10 mM dithiothreitol, alkylated with 40 mM iodoacetamide and diluted to 2 M urea with 25 mM ammonium bicarbonate. Digestion with trypsin (0.5 μg μl −1 ) was performed overnight at 37 °C in the presence of 1 mM CaCl 2 . The tryptic peptide samples were acidified with 5% formic acid (wt/vol) and aliquots were frozen at −80 °C until use. Multidimensional protein identification technology (MudPIT) analysis was performed as previously described 27 on an LTQ mass spectrometer (ThermoFinnigan) coupled to an Agilent 1100 series HPLC (n = 2 per genotype, 30 μg protein, 5-step MudPIT) or an LTQ Orbitrap Velos mass spectrometer (ThermoFinnigan) coupled to an Agilent 1200 series HPLC (n = 1 per genotype, 45 μg protein, 10-step MudPIT). The tandem mass spectrometry data were searched against the mouse IPI database using the SEQUEST search algorithm and results were filtered and grouped with DTASELECT. Peptides with crosscorrelation scores greater than 1.8 (+1), 2.5 (+2), 3.5 (+3) and delta CN scores greater than 0.08 were included in the spectral counting analysis.
Behavioral assays. To control for stress of repeated injection, all acute treatment groups received 5 d of daily vehicle injections, with acute drug treatment occurring on day 6. Subjects were evaluated 2 h after acute drug administration or the final chronic injection. Acute thermal antinociception was assessed in the tail-immersion test at 56.0 °C using a 10-s cut-off 19 . Surgery for CCI model of the sciatic nerve and allodynia assessment were performed as previously described 18 . Subjects were assessed for mechanical allodynia using von Frey filaments (North Coast Medical) and approximately 30 min later were evaluated for cold allodynia in the acetone-induced paw lifting model, with a maximum cut-off time of 20 s. Cross-tolerance studies in the CCI model were performed starting 26 h following the final chronic drug injection.
Subjects were evaluated for cross-tolerance to WIN55,212-2 or THC 26 or 48 h after the final chronic injection. Cannabimimetic activity was assessed by evaluating mice for catalepsy in the bar test 19 , antinociception in the tail immersion test at 52.0 °C 31 and hypothermia by inserting a thermocouple probe 2.0 cm into the rectum. To reduce the number of mice required for this study, we evaluated dose-response relationships using a cumulative dosing regimen in which baseline behavioral endpoints were assessed, injections were given every 40 min and subjects were evaluated for each measure 30 min after each injection, with the entire dose-response assessment being completed in less than 4 h 31 .
For precipitated withdrawal, mice were challenged with rimonabant (10 mg per kg) 2 h after the final chronic injection and the incidents of paw fluttering, including any tremors or shaking of the front paws, were recorded for a 1-h observation period 50 . electrophysiology slice preparation and testing. In the chronic experiments, subjects were anaesthetized by isoflurane inhalation and decapitated 24-26 h after the final injection. Hippocampal, cortical and caudate putamen slices (300 μm thick) were cut using a vibrating slicer (Leica) and prepared as described previously 20 . In the acute experiments, the slices were perfused with JZL184 (1 μM) or PF-3845 (10 μM) for 40-80 min.
Whole-cell voltage-clamp recordings were made using patch clamp amplifier (Multiclamp 700B) under infrared differential interference contrast microscopy. Data acquisition and analysis were performed using a digitizer (DigiData 1440A) and analysis software pClamp 10 (Molecular Devices). To record IPSCs, we clamped the neurons at −60 mV and filled the pipettes with an internal solution containing 80 mM cesium methanesulfonate, 60 mM CsCl, 5 mM QX-314, 10 mM HEPES, 0.2 mM EGTA, 2 mM MgCl 2 , 4 mM MgATP, 0.3 mM Na 2 GTP and 10 mM sodium phosphocreatine (pH 7.2 with CsOH). Glutamate receptor antagonists 6-cyano-7-nitroquinoxaline-2,3-dione (CNQX, 20 μM) and d-2-amino-5-phosphonovaleric acid (d-AP5, 25 μM) were present in the artificial cerebrospinal fluid throughout the experiments. Series resistance (15) (16) (17) (18) (19) (20) (21) (22) (23) (24) (25) (26) (27) (28) (29) (30) was monitored throughout the recordings, and data were discarded if the resistance changed by more than 20%. To record fEPSPs, the pipettes were filled with 1 M NaCl, and picrotoxin (50 μM) was present in the artificial cerebrospinal fluid. To evoke IPSCs or fEPSPs, a bipolar tungsten stimulation electrode was placed in the in the stratum radiatum of the CA1 region of hippocampus, in layer V of cingulate cortex or the caudate putamen. All recordings were performed at 32 ± 1 °C by using an automatic temperature controller.
Data analysis and statistics. All results are expressed as mean ± s.e.m. unless otherwise noted. Results were considered to be significant at P < 0.05. All lipid quantification and behavioral endpoints were initially evaluated by ANOVA (treatment or genotype) or repeated-measures ANOVA (cumulative dose responses). Following a significant ANOVA, Dunnett's post hoc test was performed for comparisons to treatment or genotypic control. Planned comparisons and specific within-drug treatments are noted in figure captions when used, using a Bonferroni test to correct for multiple comparisons. [ 35 
